| Title |
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
|
|---|---|
| Published in |
Drug, Healthcare and Patient Safety, February 2016
|
| DOI | 10.2147/dhps.s62649 |
| Pubmed ID | |
| Authors |
Daniela Pugliese, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi |
| Abstract |
Significant advances in the management of patients with ulcerative colitis (UC) have been made since the introduction of anti-tumor necrosis factor (TNF)-alpha agents, especially for those who fail or do not tolerate conventional therapies. Two drugs, infliximab first, then adalimumab afterward, showed effectiveness in inducing and maintaining long-term remission both in pivotal trials as well as in clinical practice. However, approximately 25% of patients with UC, who fail or do not tolerate all available therapies, require a colectomy for refractory disease. The therapeutic scenario of UC has been recently upgraded by the introduction of golimumab, the latest anti TNF-alpha agent to be approved. Golimumab is a totally humanized monoclonal antibody, administered by a subcutaneous injection every 4 weeks. Treatment with golimumab has shown to be effective to induce sustained clinical benefit in tough-to-treat patients with UC, including steroid and/or immunosuppressive refractory and steroid-dependent patients. In this review, we summarize all available efficacy and safety data of golimumab in UC, analyzing the potential therapeutic position for the treatment of refractory patients with UC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 21% |
| Student > Master | 10 | 16% |
| Student > Postgraduate | 6 | 10% |
| Student > Ph. D. Student | 4 | 6% |
| Student > Bachelor | 3 | 5% |
| Other | 10 | 16% |
| Unknown | 16 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Computer Science | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 17 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2016.
All research outputs
#20,011,936
of 25,457,297 outputs
Outputs from Drug, Healthcare and Patient Safety
#128
of 160 outputs
Outputs of similar age
#284,153
of 406,956 outputs
Outputs of similar age from Drug, Healthcare and Patient Safety
#3
of 4 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 160 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,956 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.